文献速递心力衰竭与心肌病

达格列净与射血分数改善心衰患者的死亡模式:DELIVER试验事后分析

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该研究为DELIVER随机临床试验的事后分析,纳入1151例射血分数改善心衰(HFimpEF)患者,比较达格列净与安慰剂对特定原因死亡的影响。HFimpEF患者中190例(16.5%)死亡,多数为非心血管死亡(54%);

要点

  • HFimpEF患者死亡以非心血管死亡为主,占54%,猝死是心血管死亡最常见原因
  • 达格列净降低HFimpEF患者心血管死亡,主要驱动因素为猝死减少
  • 结果支持SGLT2抑制剂用于HFimpEF患者以降低心血管死亡率

核心结论

  • 达格列净与HFimpEF患者较低心血管死亡相关,主要由于猝死率降低。
  • HFimpEF患者死亡模式与LVEF持续大于40%者相似,非心血管死亡占多数。

研究设计与样本

  • DELIVER随机临床试验的事后分析,2018年8月至2020年12月开展。
  • 纳入LVEF大于40%、NYHA II-IV级、利钠肽升高的心衰患者,随机接受达格列净10mg每日一次或安慰剂。
  • HFimpEF定义为既往LVEF≤40%且当前LVEF>40%,共1151例。

主要发现

  • HFimpEF患者中190例(16.5%)死亡,LVEF持续大于40%者833例(16.3%)死亡。
  • HFimpEF患者非心血管死亡103/190(54%),心血管死亡87/190(46%)。
  • 心血管死亡中猝死最常见(36/190事件,19%),其次为心衰相关(29/190事件,15%)。

关键数值与推荐

  • HFimpEF定义:既往LVEF≤40%且当前LVEF>40%。
  • 主要结局为心衰恶化事件(住院或紧急心衰就诊)或心血管死亡的复合终点。
  • 达格列净剂量为10mg每日一次。

临床怎么用

  • 对于HFimpEF患者,可考虑在指南导向药物治疗基础上加用SGLT2抑制剂以降低心血管死亡风险。
  • HFimpEF患者死亡以非心血管原因居多,临床管理需关注非心血管合并症。

局限性

  • 为事后分析,结果需前瞻性研究验证。
  • HFimpEF定义基于病例报告表,可能存在 misclassification。
  • 研究未报告全部基线特征及亚组详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Heart failure with improved ejection fraction (HFimpEF), defined as prior left ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is understudied. OBJECTIVE: To examine mode of death and the association of dapagliflozin with reductions in cause-specific death in patients with HFimpEF. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial, conducted from August 2018 to December 2020. The trial randomly assigned patients with HF with LVEF greater than 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides to treatment with dapagliflozin (10 mg, once daily) or placebo. The presence of HFimpEF was captured through study case report forms. The primary outcome was a composite of worsening HF events (hospitalization or urgent HF visits) or cardiovascular death. Clinical outcomes were adjudicated by a blinded clinical end points committee. Data were analyzed from May 2022 to August 2023. INTERVENTION: Dapagliflozin vs placebo. MAIN OUTCOMES AND MEASURES: The mode of death in relation to HFimpEF status was examined, as well as the association of randomized treatment with cause-specific death in Cox regression models. RESULTS: Of 1151 patients with HFimpEF in DELIVER, 190 (16.5%) died, compared with 833 patients (16.3%) of 5112 with LVEF consistently greater than 40%. The overall distribution of mode of death was similar in those with HFimpEF compared with those with LVEF consistently greater than 40% (noncardiovascular death: 103 of 190 [54%] vs 428 of 833 [51%]; cardiovascular death: 87 of 190 [46%] vs 405 of 833 [49%], respectively). Most deaths in individuals with HFimpEF were noncardiovascular (103 of 180 [54%]). For cardiovascular deaths, sudden deaths were most common (36 of 190 events [19%]), followed by HF-related (29 of 190 events [15%]). Among patients with HFimpEF, treatment with dapagliflozin was associated with lower rates of cardiovascular death relative to placebo, a difference primarily due to lower rates of sudden death (hazard ratio, 0.38; 95% CI, 0.18-0.79; P for interaction = .01). CONCLUSIONS AND RELEVANCE: The findings in this study support current guideline recommendations for use of sodium-glucose transport protein 2 inhibitor therapy, and further suggest that the addition of a sodium-glucose transport protein 2 inhibitor therapy to other guideline-directed medical therapies may help reduce cardiovascular mortality in patients with HFimpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Vardeny, Desai, Jhund, et al. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. JAMA Cardiol. 2024. PMID: 38265835. doi:10.1001/jamacardio.2023.5318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。